In this regard, several authors have shown that GSK3 inhibitors are able to regulate MYCN mRNA levels and reduce NB cell viability through multiple mechanisms, including p53 and Wnt signaling, BDNF/TrkB/PI3K/Akt, suggesting that targeting this kinase might potentiate chemotherapy [271,272,273,274]. Here, TP53 is linked to neuroblastoma.